



# Pharmacy Grand Rounds

200 First Street SW

Rochester, Minnesota 55905

<https://ce.mayo.edu/pharmacy-grandrounds-2026>

## Breaking The Swell Spell-New Treatments for Hereditary Angioedema

**Session Date:** 05/12/2026

**Session Time:** 11:00 – 11:45 AM (CST)

### Target Audience

This continuing education (CE) session was planned to meet the needs of professional staff who deal with the selection and monitoring of medication(s) as part of their patient care duties, including pharmacists, RNs, APRNs, PAs, MDs.

### Activity Overview

Hereditary angioedema (HAE) is a rare, bradykinin-mediated disorder characterized by recurrent episodes of non-pruritic, non-pitting swelling involving the skin, gastrointestinal tract, and upper airway, with risk for significant morbidity and mortality. Historically, management strategies have been guided by the US HAE Association Medical Advisory Board 2020 Guidelines, which recommend C1 inhibitor replacement, kallikrein inhibition, and bradykinin receptor antagonism for both on-demand and prophylactic treatment; however, these guidelines do not include more recently approved therapies. Advances in therapeutic development have introduced additional targeted agents, including therapies that inhibit upstream components of the contact activation pathway, reduce prekallikrein production, or provide oral options for acute treatment. These newer approaches expand available treatment strategies and may improve convenience, adherence, and patient-centered care. This presentation will review the pathophysiology of HAE with emphasis on bradykinin generation and therapeutic targets, and summarize guideline-based management approaches alongside emerging therapies.

### Learning Objectives

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Describe the pathophysiology of hereditary angioedema (HAE), including the role of the contact activation system, bradykinin generation, and therapeutic targets
2. Differentiate between available prophylactic and on-demand therapies for HAE, with emphasis on newly approved agents (garadacimab, donidalorsen, sebetralstat)
3. Apply evidence from pivotal clinical trials (VANGUARD, OASIS-HAE, KONFIDENT) to clinical decision-making regarding agent selection

### Faculty Information

Carley Laffin, PharmD

PGY1 Pharmacy Resident

Mayo Clinic Health System- Eau Claire, WI

Carley received a Doctor of Pharmacy degree from The University of Wisconsin-Madison School of Pharmacy and is a current PGY1 pharmacy resident at Mayo Clinic Health System-Eau Claire, WI. Her practice interests include ambulatory care, rural healthcare, and infectious disease.



## Approved Provider Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### Credit Statements

#### AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### AAPA



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

#### ACPE



**ACPE Universal Activity Number (UAN):** JA0000238-0000-26-051-L01-P

Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 0.75 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity

#### ANCC

Mayo Clinic College of Medicine and Science designates this activity for a maximum of 0.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

#### IPCE



This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

## Educational Format and CE Requirements

This CE session is available as a live presentation, including live webcast.

Participants must complete the following to record attendance and obtain CE credit:

1. Attend the entire session.
2. Text the session code to 507-200-3010 within 48 hours of the live presentation to record attendance.
  - a. This number is only used for receiving text messages related to tracking attendance
  - b. Employees are encouraged to create a contact in their mobile phone, as the same number is used to record

attendance for every session

3. Complete the online evaluation for the respective session within 2 weeks of live presentation.

Pharmacist CE credit is electronically transferred to the National Association of Boards of Pharmacy CPE Monitor. To track CE, please go to [NABP CPE Monitor](#).

Non-pharmacist attendees can print out a record of attendance at [ce.mayo.edu](http://ce.mayo.edu) after completing the evaluation and claiming credit.

[Live Webcast](#) – Register from the Education SharePoint site

## Disclosure Summary

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed:

The faculty report the following relationships:

- Carley Laffin, PharmD
  - Declares no financial relationship(s) pertinent to this session
  - Declares off-label use of medications will not be discussed during this presentation

Course Director and Planning Committee Members declare the following relevant financial relationship(s) pertinent to this session.

- No relevant financial relationship(s) with ineligible companies:
  - Jennifer Elmer, DNP, APRN, CCNS
  - Andrew Herber, PA-C
  - Sarah Jane Kotval, BSW, RSS Coordinator
  - Scott Nei, PharmD, BCPS, BCCCP, FCCM, FMSHP
  - Sara Thompson, PharmD, MEd, BCACP
- Relevant financial relationship(s) with ineligible companies:
  - Wayne Nicholson, MD, PharmD, BCPS - Intellectual Property - Anivive Lifesciences, Inc.

All relevant financial relationships have been mitigated.

For additional disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee members visit [ce.mayo.edu](http://ce.mayo.edu), About Us, Disclosures - or -

<https://ce.mayo.edu/content/disclosures>

## System and Technical Requirements

For participants viewing the webcast, sessions are delivered via Mayo Clinic intranet web browser and Adobe® PDF. For participants viewing outside the Mayo Clinic firewall, a VPN connection is required for remote access. Recommended web browser includes Google Chrome. This session is planned and coordinated by **the Department of Pharmacy, Mayo Clinic**.